Is Chronic Hepatitis B Infection a Protective Factor for the Progression of Advanced Pancreatic Ductal Adenocarcinoma? an Analysis from a Large Multicenter Cohort Study

Qiwen Chen,Zhouyu Ning,Lei Wang,Ying Hui,Shu Dong,Chenyue Zhang,Xing Shen,Yuanbiao Guo,Hao Chen,Xiaoyan Zhu,Yehua Shen,Weidong Shi,Yi-Jun Hua,Kun Wang,Jiahao Lin,Litao Xu,Lianyu Chen,Lanyun Feng,Xiumei Zhang,Jing Xie,Bo Sun,Yunbo Sun,Wenchao Gu,Mei Kang,Zheng Tang,Zhujun Chen,Zhe Chen,Luming Liu,Jinming Yu,Zhaoshen Li,Zhiqiang Meng
DOI: https://doi.org/10.18632/oncotarget.13000
2016-01-01
Oncotarget
Abstract:Purpose: Whether the progression of advanced pancreatic ductal adenocarcinoma (PDAC) patients could be affected by HBV exposure remains to be determined.Therefore, we conducted this study to assess the effect of HBV infection on PDAC progression among a large cohort in China.Methods: A multicenter cohort study was conducted to explore whether liver metastasis and overall survival in locally advanced and metastatic PDAC could be affected by HBV infection.In this study, we collected 1,526 advanced PDAC patients at three participating hospitals -Shanghai Cancer Center, Changhai Hospital and Ruijin Hospital from 2004 to 2013.The association between HBV status and advanced PDAC progression was then examined. Results: In multivariable Logistic regression model, chronic hepatitis B(CHB) infection was inversely associated with synchronous liver metastasis compared to nonHBV infection (OR 0.41, 95% CI 0.19-0.85)for stage IV patients.In a multivariable Cox model, CHB infection (HR=0.11,95% CI 0.02-0.82) is considered as a protective factor of metachronous liver metastasis compared to Non HBV infection for stage III patients.For stage IV patients, CHB infection was inversely associated with overall survival compared to non HBV infection (HR 0.70, 95% CI 0.51-0.95).Inactive
What problem does this paper attempt to address?